Skip to main content

Table 4 Application of DNMTi and HDACi to OC treatment

From: Ovarian cancer: epigenetics, drug resistance, and progression

Drugs Function Reference
DNMTi   
 SGI-110 1. Drug sensitizer used in combination with cisplatin [156]
  2. Enhances the immune recognition of tumor cells by regulating MHC class I and immunomodulatory molecules in EOC cells, and is superior to AZA or DAC [157]
 5-Aza-2’-deoxycytidine (5-AZA-CdR) Upregulate endogenous retrovirus (ERV) with G9Ai, synergistically induce antitumor [158]
 5-Azacytidine (5AZA-C) Induced the recruitment of activated (IFNγ+) CD4+T cells, CD8+ T cells and NK cells combining with α-difluoromethylornithine (DFMO) [159]
HDACi   
 Entinostat (class I HDACi) Synergistic effect with cisplatin in HGSOC [160]
 Vorinostat Inhibit tumor growth and prolong survival via targeting CD146 [161]
 Panobinostat 1. Synergistic effect with carboplatin in EOC [162]
  2. Reduce homologous recombination (HR) cyclin E-overexpression, as a means of enhancing PARPi activity [163]
 Thailandepsins Inhibit cell viability and induce apoptosis [164]
 Suberoylanilide hydroxamic acid (SAHA) Combined olaparib induced apoptosis and pH2AX expression more strongly to a greater extent than either drug alone [165]